Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2558)	10/5/2009 1:12:52 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

GENT is trying to bounce up from its recent near term DT.<g> The stock is still up 7.76% on volume of 44,500 still below its ADV bigcharts.marketwatch.com Its 2nd Q results showed better revenues. (It had been trimming its losses for the previous 3Qs in spite of lower revenues) The revenues were €2.61M vs. €1.86M. The increase was primarily attributable to the launch of Defibrotide throughout the European and Asia-Pacific markets by IDIS Limited. Operating loss was €0.41M vs. €4.63 million and the loss was €0.49M vs. €4.53M Cash and cash equivalents were €1.36M vs. €11.49M as of Dec31. In March GENT made a final installment payment of €4.0M to Crinos related to the acquisition of marketing authorizations and trademarks for Prociclide and Noravid. GENT anticipates that its current cash will meet its operating requirements through January of 2010. However, beyond that point, it will likely need capital from external sources.<g> GENT submitted abstracts for the American Society of Hematology Conference in New Orleans, Dec 5-8, with data from the PIII for the treatment of severe VOD and for the PII/III European prevention of VOD in pediatric stem cell patients. The results from both studies are encouraging and demonstrate strong trends in favor of the Defibrotide-treated patients in both the treatment of severe VOD and the prevention of VOD. Back in August GENT said that results from a late-stage study of its drug Defibrotide failed to show a level of statistical significance required for proof of efficacy. But the results did show "strong trends in favor of the Defibrotide-treated patients for complete response and survival." <g> The stock had a nice move from its March 25 $0.45 level to its Sep29 H at $4 but it seems better at this point to wait for further developmenst.<g> bigcharts.marketwatch.com Bernard